Biogen (BIIB) PT Lowered to $385 at Guggenheim
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.03 +6.97%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Guggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Glanbia PLC (GLB:ID) (GLAPF) PT Raised to EUR19 at Morgan Stanley
- GS Yuasa Corporation (6674:JP) PT Raised to JPY8,200 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
